Caladrius Biosciences, Inc. (CLBS)
(Delayed Data from NSDQ)
$2.94 USD
+0.09 (2.98%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.97 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
Lisata Therapeutics, Inc. [CLBS]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 5.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Signs of a Fruitful Union; Prospective Merger Partner Announces New Collaboration For Pancreatic Cancer Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neutral: Caladrius Drunk with Cash ($73M) but What Happens When Shareholders Wake Up? Hangover. We Remain Neutral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Price: 5.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; As Programs Continue to Execute, Cend Merger Remains On Track To Close This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Delivering Precious Cargo; A Closer Look at CENDIFOX Phase 1b/2a Study Design at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FREEDOM Enrollment Halted; Interim Results in 3Q22 and Path Forward by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lisata Emerges From Synergies With Cend; Merger Directs New Focus to Oncology
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neutral: Caladrius Acquires an Early-Stage Cancer Company (Cend Therapeutics) - Three Employees for Half of Caladrius Value - We Remain Neutral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Price: 5.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CLBS201 Continues to Advance as Expected; First Patient Dosed in Phase 1b Study in DKD
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Imminent Regulatory Decision for HONEDRA in 2Q22; CMD and DKD Trudging Forward; Target Reduced to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neutral: Is the Autologous Model Flawed? Yes
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Price: 5.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neutral: Delays, Delays & Delays + Burning Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Price: 5.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Strategy Adjustments Optimize Chances of Success Despite COVID-19; Target Adjusted to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Clinical Programs Power Through Despite Continued Blocking and Tackling with COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; FREEDOM Phase 2b Enrollment On Track With Other Clinical Programs Likely to Follow Suit
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Programs Move Steadily Towards Prime Time; Target Adjusted to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neutral: Dam the Shareholders, Full Speed Ahead
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Price: 10.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CLBS16 Initiates Dosing in FREEDOM; Strategic Priorities for 2021 Across all Programs; Target Adjusted to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Lisata Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neutral: Technology Founder Leaves as Caladrius Shows a Downward Spiral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Price: 10.00